当前位置: 首页 >> 检索结果
3243. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.
作者: Tiia Ngandu.;Jenni Lehtisalo.;Alina Solomon.;Esko Levälahti.;Satu Ahtiluoto.;Riitta Antikainen.;Lars Bäckman.;Tuomo Hänninen.;Antti Jula.;Tiina Laatikainen.;Jaana Lindström.;Francesca Mangialasche.;Teemu Paajanen.;Satu Pajala.;Markku Peltonen.;Rainer Rauramaa.;Anna Stigsdotter-Neely.;Timo Strandberg.;Jaakko Tuomilehto.;Hilkka Soininen.;Miia Kivipelto.
来源: Lancet. 2015年385卷9984期2255-63页
Modifiable vascular and lifestyle-related risk factors have been associated with dementia risk in observational studies. In the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), a proof-of-concept randomised controlled trial, we aimed to assess a multidomain approach to prevent cognitive decline in at-risk elderly people from the general population.
3245. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
作者: Christian T Ruff.;Robert P Giugliano.;Eugene Braunwald.;David A Morrow.;Sabina A Murphy.;Julia F Kuder.;Naveen Deenadayalu.;Petr Jarolim.;Joshua Betcher.;Minggao Shi.;Karen Brown.;Indravadan Patel.;Michele Mercuri.;Elliott M Antman.
来源: Lancet. 2015年385卷9984期2288-95页
New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vitamin K antagonists. A concern has emerged, however, that measurement of drug concentration or anticoagulant activity might be needed to prevent excess drug concentrations, which significantly increase bleeding risk. In the ENGAGE AF-TIMI 48 trial, higher-dose and lower-dose edoxaban were compared with warfarin in patients with atrial fibrillation. Each regimen incorporated a 50% dose reduction in patients with clinical features known to increase edoxaban drug exposure. We aim to assess whether adjustment of edoxaban dose in this trial prevented excess drug concentration and the risk of bleeding events.
3249. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
作者: Jessica L Mega.;Joseph R Walker.;Christian T Ruff.;Alexander G Vandell.;Francesco Nordio.;Naveen Deenadayalu.;Sabina A Murphy.;James Lee.;Michele F Mercuri.;Robert P Giugliano.;Elliott M Antman.;Eugene Braunwald.;Marc S Sabatine.
来源: Lancet. 2015年385卷9984期2280-7页
Warfarin is the most widely used oral anticoagulant worldwide, but serious bleeding complications are common. We tested whether genetic variants can identify patients who are at increased risk of bleeding with warfarin and, consequently, those who would derive a greater safety benefit with a direct oral anticoagulant rather than warfarin.
3250. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial.
作者: Sayoki Mfinanga.;Duncan Chanda.;Sokoine L Kivuyo.;Lorna Guinness.;Christian Bottomley.;Victoria Simms.;Carol Chijoka.;Ayubu Masasi.;Godfather Kimaro.;Bernard Ngowi.;Amos Kahwa.;Peter Mwaba.;Thomas S Harrison.;Saidi Egwaga.;Shabbar Jaffar.; .
来源: Lancet. 2015年385卷9983期2173-82页
Mortality in people in Africa with HIV infection starting antiretroviral therapy (ART) is high, particularly in those with advanced disease. We assessed the effect of a short period of community support to supplement clinic-based services combined with serum cryptococcal antigen screening.
3252. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
作者: Faiez Zannad.;Christopher P Cannon.;William C Cushman.;George L Bakris.;Venu Menon.;Alfonso T Perez.;Penny R Fleck.;Cyrus R Mehta.;Stuart Kupfer.;Craig Wilson.;Hung Lam.;William B White.; .
来源: Lancet. 2015年385卷9982期2067-76页
The EXAMINE trial showed non-inferiority of the DPP-4 inhibitor alogliptin to placebo on major adverse cardiac event (MACE) rates in patients with type 2 diabetes and recent acute coronary syndromes. Concerns about excessive rates of in-hospital heart failure in another DPP-4 inhibitor trial have been reported. We therefore assessed hospital admission for heart failure in the EXAMINE trial.
|